Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study
PLOS One · 2026
DOI: 10.1371/journal.pone.0340917 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2026. Verfasst von Jordan Bellis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Inflammation, Dronabinol, Cannabinoids. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Sickle Cell Disease (SCD) is a hemoglobinopathy affecting millions of people globally. Pain, both acute and chronic, affects over half of those living with SCD, but treatment of chronic pain is an ongoing challenge. While opioid treatments are widely used for chronic pain, it’s efficacy is limited, so alternatives must be explored. This protocol outlines a procedure for investigation of dronabinol, an FDA-approved synthetic tetrahydrocannabinol (THC), for the treatment of pain in patients living with SCD and chronic pain. The study is an 8-week, randomized, double-blind placebo-controlled study which aims to assess both the efficacy and safety of this opioid alternative to pain treatment. The study will also track biomarkers of inflammation as THC has demonstrated anti-inflammatory properties, and inflammation is a driver of SCD pain and disease severity. Results from this study have the potential to further clinical understanding of cannabinoids for pain management in Sickle Cell Disease treatment and spark new questions for research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
- Department of Medicine Nursing, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
ORCID-Profile: Jordan Bellis, Lydia Monk, Angela Liu, Charleen Jacobs-McFarlane
Förderung
- National Heart, Lung, and Blood Institute
Zitieren
APA
Bellis, J., Monk, L., Jhawar, R., Pollock, G., Liu, A., Jacobs-McFarlane, C., McCrary, B., Glassberg, J., & Curtis, S. (2026). Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study. PLOS One. https://doi.org/10.1371/journal.pone.0340917
Vancouver
Bellis J, Monk L, Jhawar R, Pollock G, Liu A, Jacobs-McFarlane C, et al. Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study. PLOS One. 2026. doi:10.1371/journal.pone.0340917
BibTeX
@article{Bellis2026,
author = {Bellis, Jordan and Monk, Lydia and Jhawar, Ritika and Pollock, Galia and Liu, Angela and Jacobs-McFarlane, Charleen and McCrary, Brittany and Glassberg, Jeffrey and Curtis, Susanna},
title = {Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0340917}
}
EUVIMED